H
Hana Müllerová
Researcher at AstraZeneca
Publications - 125
Citations - 7112
Hana Müllerová is an academic researcher from AstraZeneca. The author has contributed to research in topics: COPD & Exacerbation. The author has an hindex of 31, co-authored 101 publications receiving 5883 citations. Previous affiliations of Hana Müllerová include Kurume University & GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Prevalence and Burden of Dyspnoea Among Patients with Chronic Obstructive Pulmonary Disease in Five European Countries
Yogesh Suresh Punekar,Hana Müllerová,Mark Small,Tim Holbrook,Robert Wood,Ian Naya,Manuel Valle +6 more
TL;DR: Moderate-to-severe dyspnoea is highly prevalent in patients with COPD across the five European countries studied and is associated with a significant disease burden and more than doubles the economic burden on health care systems.
Use of Proteomic Patterns of Serum Biomarkers in Patients with Chronic Obstructive Pulmonary Disease
Victor Pinto-Plata,John Toso,Kwan Lee,John A. Bilello,Hana Müllerová,Mary M De Souza,R. Vessey,Bartolome R. Celli +7 more
TL;DR: Seemungal et al. as mentioned in this paper studied the effect of COPD exacerbations on quality of life in patients with chronic obstructive pulmonary disease and found that women with mild COPD had higher airway hyperresponsiveness compared to men with moderate COPD.
Journal ArticleDOI
Concomitant diagnosis of asthma and COPD: a quantitative study in UK primary care.
TL;DR: A concurrent asthma and COPD diagnosis appears to affect a relative minority of patients with COPD or asthma, and the extent of possible misdiagnosis and missed opportunities for diagnosis is determined.
Journal ArticleDOI
Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort
Bartolome R. Celli,Nicholas Locantore,Julie C. Yates,Per Bakke,Peter M.A. Calverley,Courtney Crim,Harvey O. Coxson,David A. Lomas,William MacNee,Bruce E. Miller,Hana Müllerová,Stephen I. Rennard,Edwin K. Silverman,Emiel F.M. Wouters,Ruth Tal-Singer,Alvar Agusti,Jørgen Vestbo +16 more
TL;DR: In patients with COPD, 1- and 3-year changes in exacerbation frequency, systemic inflammation, BODE and SGRQ scores and FEV1 decline are independent markers of disease activity associated with 8-year all-cause mortality.
Journal ArticleDOI
Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study.
TL;DR: Adherence to newly initiated LAMA monotherapy was low, with one in four patients adding to or switching from LAMA and many patients discontinuing therapy, suggesting that additional medication to a single LABD may be required in some patients with COPD to achieve optimal disease control.